| Literature DB >> 35200484 |
Waleed Y Rizg1,2, N Raghavendra Naveen3, Mallesh Kurakula4, Haitham A Bukhary5, Awaji Y Safhi6, Eman Alfayez7, Amal M Sindi8, Sarah Ali8, Samar S Murshid9, Khaled M Hosny1,2.
Abstract
The goal of the current study is to develop a chitosan alginate nanoparticle system encapsulating the model drug, simvastatin (SIM-CA-NP) using a novel polyelectrolytic complexation method. The formulation was optimized using the central composite design by considering the concentrations of chitosan and alginate at five different levels (coded as +1.414, +1, 0, -1, and -1.414) in achieving minimum particle size (PS-Y1) and maximum entrapment efficiency (EE-Y2). A total of 13 runs were formulated (as projected by the Design-Expert software) and evaluated accordingly for the selected responses. On basis of the desirability approach (D = 0.880), a formulation containing 0.258 g of chitosan and 0.353 g of alginate could fulfill the prerequisites of optimum formulation in achieving 142.56 nm of PS and 75.18% EE. Optimized formulation (O-SIM-CAN) was further evaluated for PS and EE to compare with the theoretical results, and relative error was found to be within the acceptable limits, thus confirming the accuracy of the selected design. SIM release from O-SIM-CAN was retarded significantly even beyond 96 h, due to the encapsulation in chitosan alginate carriers. The cell viability study and Caspase-3 enzyme assay showed a notable difference in contrast to that of plain SIM and control group. All these stated results confirm that the alginate-chitosan nanoparticulate system enhanced the anti-proliferative activity of SIM.Entities:
Keywords: alginate; caspase-3-enzyme assay; central composite design; chitosan; simvastatin
Year: 2022 PMID: 35200484 PMCID: PMC8924759 DOI: 10.3390/gels8020103
Source DB: PubMed Journal: Gels ISSN: 2310-2861
Interpretation of FTIR spectra of pure SIM and formulation.
| S. No | Wavenumber Identified in SIM (cm−1) | Functional Group Assigned | Wavenumber Identified in Formulation (cm−1) |
|---|---|---|---|
| 1. | 3550 | O-H Stretch | 3559 |
| 2. | 2931 | C-H stretch: Methyl/methylene asymmetric | 2942 |
| 3. | 1465 | Methylene symmetric C-H bend | 1472 |
| 4. | 1267 | -C-O-C bend (Lactone) | 1271 |
| 5. | 1165 | -C-O-C bend (Ester) | 1169 |
| 6. | 1072 | C-O Stretch (secondary alcohol) | 1073 |
| 7. | 1566 | N-H stretch | 1569 |
Figure 1FTIR spectra of (a) Pure SIM and (b) Final formulation.
Projected experimental runs for central composite design and their observed responses.
| Factor 1 | Factor 2 | Response 1 | Response 2 | ||
|---|---|---|---|---|---|
| Std | Run | A: Chitosan | B: Sodium Alginate | PS | EE |
| (g) | (g) | (nm) | (%) | ||
| 10 | 1 | 0.25 | 0.3 | 109 | 66 |
| 4 | 2 | 0.4 | 0.5 | 296 | 79 |
| 2 | 3 | 0.4 | 0.1 | 110 | 41 |
| 6 | 4 | 0.462132 | 0.3 | 219 | 56 |
| 3 | 5 | 0.1 | 0.5 | 309 | 87 |
| 11 | 6 | 0.25 | 0.3 | 118 | 71 |
| 12 | 7 | 0.25 | 0.3 | 132 | 67 |
| 7 | 8 | 0.25 | 0.0171573 | 206 | 37 |
| 9 | 9 | 0.25 | 0.3 | 127 | 78 |
| 5 | 10 | 0.037868 | 0.3 | 307 | 60 |
| 8 | 11 | 0.25 | 0.582843 | 351 | 91 |
| 1 | 12 | 0.1 | 0.1 | 209 | 46 |
| 13 | 13 | 0.25 | 0.3 | 128 | 70 |
Model Summary Statistics of selected responses.
| Responses | Source | Sequential | Lack of Fit | Adjusted R² | Predicted R² | |
|---|---|---|---|---|---|---|
| Lag Time | Linear | 0.0811 | 0.0002 | 0.2738 | 0.0095 | |
| 2FI | 0.5958 | 0.0002 | 0.2194 | −0.0863 | ||
| Quadratic | 0.0001 | 0.2114 | 0.9209 | 0.8919 | Suggested | |
| Cubic | 0.5849 | 0.0037 | 0.9106 | −1.1565 | Aliased | |
| T- 95% CDR | Linear | <0.0001 | 0.2628 | 0.8750 | 0.8363 | |
| 2FI | 0.8162 | 0.2116 | 0.8620 | 0.8172 | ||
| Quadratic | 0.0152 | 0.8480 | 0.9463 | 0.9223 | Suggested | |
| Cubic | 0.8315 | 0.5374 | 0.9302 | 0.7696 |
Model (Quadratic) fit summary of the responses.
| Parameter | PS | EE |
|---|---|---|
| Std. Dev. | 24.90 | 3.91 |
| Mean | 201.62 | 65.31 |
| C.V. % | 7.35 | 5.98 |
| Adeq Precision | 13.1592 | 20.6875 |
| Lack of Fit F-value | 15.55 | 12.2650 |
| Lack of Fit | 0.0614 | 0.8480 |
| Model F value | 28.92 | 43.33 |
| Model | 0.0002 | <0.0001 |
Figure 2Normal probability and model residuals versus test orders for (A) PS and (B) EE.
ANOVA coefficients table for both the responses.
| Intercept | A | B | AB | A² | B² | |
|---|---|---|---|---|---|---|
| PS | 122.8 | −29.5563 | 61.3826 | 21.5 | 60.1625 | 67.9125 |
| 0.0121 | 0.0002 | 0.1279 | 0.0004 | 0.0002 | ||
| EE | 70.4 | −2.33211 | 19.4209 | −0.75 | −5.6375 | −2.6375 |
| 0.1353 | <0.0001 | 0.7125 | 0.0067 | 0.1183 |
Figure 3Contour plots and 3-D Response surface plots for (A) PS and (B) EE.
Relative error calculation for optimized formulation.
| S. No | Response | Predicted/Theoretical Value | Experimental/Practical Value | Relative Error (%) | Limit for Relative Error (%) |
|---|---|---|---|---|---|
| 1. | PS (nm) | 142.56 | 143.23 | −0.47 | ±5 |
| 2. | EE (%) | 75.18 | 74.72 | 0.61 |
Figure 4Scanning electron micrograph showing (a) the shape and (b) surface morphology of optimized SIM nanoformulation.
Figure 5In vitro dissolution study for optimized formulation and pure SIM.
Figure 6O-SIM-CAN, plain SIM, and control [5 Fluorouracil] effect on the percentage cell viability of HSC-3 cell lines. (The values indicated were the Mean ± S.D, n = 9).
Figure 7Cytoskeleton images of control, SIM, and O-SIM-CAN after 24 h treatment.
Figure 8Cytoskeleton images of control, SIM, and O-SIM-CAN after 72 h treatment.
Figure 9Concentrations of enzyme caspase-3 in HCS 3 cells treated with plain SIM, O-SIM-CAN, and control (solvent-free); (n = 6 ± SD).
Entire work plan interns of coded and real values of parameters chosen and limitations of dependent factors for central composite design.
| Selected | Levels | Responses/Dependent Variables | Constraints | ||||
|---|---|---|---|---|---|---|---|
| −1.141 | +1 | 0 | +1 | +1.141 | |||
| Chitosan (g)-X1 | 0.037 | 0.1 | 0.25 | 0.4 | 0.462 | Particle size (nm) | Minimum |
| Eudragit RLPO (g)-X2 | 0.017 | 0.1 | 0.3 | 0.5 | 0.582 | EE (%) | Maximum |